ARTICLE | Deals
Pfizer, GSK optimizing formulations via Novavax, Alteogen tie-ups: Deals Report
Plus: New capital structure at ViiV, and more
January 21, 2026 10:40 PM UTC
Tuesday’s takeout of Rapt by GSK for $2.2 billion signaled that even if the J.P. Morgan Healthcare Conference lacked a signature deal, biotech M&A could show continued strength into 2026.
The acquisition of Rapt Therapeutics Inc. (NASDAQ:RAPT) by GSK plc (LSE:GSK; NYSE:GSK) gives the pharma an allergy asset that the biotech sourced in China in 2024...